Skip to main content

Table 1 Characteristics of patients

From: Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia

Characteristics Males (n = 47) Females (n = 54) p
Age (years) 56.7 ± 11.3 63.1 ± 11.6 0.008
Height (cm) 166.9 ± 5.9 152.9 ± 8.0 <0.001
Weight (kg) 77.3 ± 12.7 64.6 ± 10.1 <0.001
Body mass index (kg/m2) 27.7 ± 3.6 27.6 ± 3.4 0.919
Waist circumference (cm) 94.6 ± 10.4 95.7 ± 8.1 0.622
Systolic blood pressure (mmHg) 129.1 ± 14.3 127.9 ± 15.4 0.705
Diastolic blood pressure (mmHg) 77.1 ± 8.5 74.7 ± 10.4 0.229
Total cholesterol (mg/dl) 223.3 ± 32.6 243.6.1 ± 35.1 0.003
LDL-cholesterol (mg/dl) 138.7 ± 26.9 152.2 ± 29.7 0.020
HDL-cholesterol (mg/dl) 48.8 ± 10.1 53.6 ± 10.7 0.024
Non HDL-cholesterol (mg/dl) 174.5 ± 29.8 190.1 ± 31.1 0.012
Triglycerides* (mg/dl) 172.4 (56–1804) 151.4 (62–473) 0.214
RLP-cholesterol* (mg/dl) 6.7 (2.2-82.5) 6.5 (2.4-28.7) 0.868
Free fatty acid* (mEq/l) 428.3 (92–1423) 437.0 (87–1134) 0.834
Plasma glucose (mg/dl) 108.5 ± 26.7 103.4 ± 29.1 0.360
Insulin* (μU/ml) 12.9 (1.55-200) 10.2 (2.82-72.6) 0.180
HOMA index* 3.36 (0.35-80.5) 2.51 (0.64-36.2) 0.146
hs CRP* (mg/dl) 720.5 (50-19100) 713.4 (50-7910) 0.990
Aldosterone (pg/dl)* 95.6 (42.2-315.0) 85.6 (37.9-296.0) 0.238
HGF (ng/ml) 0.32 ± 0.05 0.31 ± 0.06 0.731
Adiponectine (μg/ml)* 1.97 (0.28-10.6) 3.21 (0.30-8.34) 0.001
EPA/AA* 0.35 (0.10-2.05) 0.30 (0.10-1.59) 0.226
  1. Data are means (SD), geometric mean and range. *: These variables are shown in the original scale after analysis using log (natural)-transformed values.
  2. Abbreviations: RLP Remnant-like particle cholesterol, HOMA Homeostasis model assessment, HGF Hepatocyte growth factor, EPA/AA Eicosapentaenoic acid to arachidonic acid.